Vanda Pharmaceuticals (VNDA) FCF Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted FCF Margin of 97.53% for Q1 2026, down 89.03% sequentially from 51.59% in Q4 2025, and down 3042.0% YoY from 3.31% in Q1 2025.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) FCF Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported FCF Margin for 17 years, with the latest figure at 97.53% in Q1 2026.
- Quarterly FCF Margin fell 3042.0% year-over-year to 97.53% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 58.45% (down 2995.0% YoY) and the FY2025 annual result came in at 51.1%, down 4293.0% from the prior year.
- FCF Margin retreated to 97.53% in Q1 2026 per VNDA's latest filing, from 51.59% in the prior quarter.
- Over five years, FCF Margin peaked at 50.8% in Q1 2023 and troughed at 97.53% in Q1 2026.
- A 5-year average of 16.38% and a median of 8.8% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2025: FCF Margin surged 4421 bps in 2023, then tumbled 8304 bps in 2025.
- Over 5 years, FCF Margin stood at 14.19% in 2022, then plunged by 162 bps to 8.8% in 2023, then soared by 57 bps to 3.82% in 2024, then plunged by 1251 bps to 51.59% in 2025, then tumbled by 89 bps to 97.53% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 97.53%, 51.59%, and 56.5% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -61.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -61.87% |
| Mar 31, 2026 | -97.53% |
| Dec 31, 2025 | -51.59% |
| Sep 30, 2025 | -56.50% |
| Jun 30, 2025 | -29.57% |
| Mar 31, 2025 | -67.11% |
| Dec 31, 2024 | -3.82% |
| Sep 30, 2024 | -30.94% |
| Jun 30, 2024 | -13.94% |
| Mar 31, 2024 | 15.93% |
| Dec 31, 2023 | -8.80% |
| Sep 30, 2023 | -5.34% |
| Jun 30, 2023 | -28.82% |
| Mar 31, 2023 | 50.80% |
| Dec 31, 2022 | 14.19% |
| Sep 30, 2022 | 19.43% |
| Jun 30, 2022 | 8.53% |
| Mar 31, 2022 | 6.60% |
| Dec 31, 2021 | 38.92% |
| Sep 30, 2021 | 13.42% |